started · updated
Chinese drugmakers shift marketing to AI medical platforms
Pharmaceutical companies in China are increasingly utilizing artificial intelligence-powered medical platforms to reach doctors. This shift follows a government anti-corruption crackdown that has imposed tighter restrictions on traditional pharmaceutical marketing and hospital visits by drug representatives.
Major digital health providers, including Alibaba Health and JD Health, have launched AI assistants designed to support medical professionals with clinical research and disease-specific information. Alibaba Health is exploring a business model where pharmaceutical firms could pay to have sponsored medical research and clinical evidence featured alongside AI-generated responses to physician inquiries. While Alibaba Health has not yet implemented these partnerships, the company reports strong interest from both domestic and international pharmaceutical firms.
The adoption of AI tools among Chinese medical professionals is rising rapidly. A survey by Alibaba Health indicated that 93 percent of surveyed doctors use AI tools, an increase from approximately 70 percent the previous year. Industry analysts at Frost and Sullivan project that digital health marketing in the region could grow at an annual rate of 27.5 percent between 2027 and 2030, potentially reaching 274.4 billion yuan.
Entities
Alibaba Health · China · Frost and Sullivan · JD Health · Wang Xiangzhi